GNPX vs. AVTX, KALA, HUGE, BYSI, MDNA, MGTA, VINC, SYBX, MBIO, and NLTX
Should you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Avalo Therapeutics (AVTX), Kala Pharmaceuticals (KALA), FSD Pharma (HUGE), BeyondSpring (BYSI), Medicenna Therapeutics (MDNA), Magenta Therapeutics (MGTA), Vincerx Pharma (VINC), Synlogic (SYBX), Mustang Bio (MBIO), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.
Genprex vs.
Genprex (NASDAQ:GNPX) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
9.1% of Genprex shares are owned by institutional investors. Comparatively, 67.5% of Avalo Therapeutics shares are owned by institutional investors. 10.6% of Genprex shares are owned by insiders. Comparatively, 45.4% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Genprex has higher earnings, but lower revenue than Avalo Therapeutics.
In the previous week, Genprex had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 7 mentions for Genprex and 4 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.56 beat Genprex's score of 0.52 indicating that Avalo Therapeutics is being referred to more favorably in the news media.
Genprex has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.
Genprex received 192 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 64.90% of users gave Genprex an outperform vote while only 30.77% of users gave Avalo Therapeutics an outperform vote.
Genprex has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -170.36%. Genprex's return on equity of -109.81% beat Avalo Therapeutics' return on equity.
Genprex presently has a consensus price target of $3.00, suggesting a potential upside of 273.51%. Avalo Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 440.07%. Given Avalo Therapeutics' higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Genprex.
Summary
Genprex beats Avalo Therapeutics on 8 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools